MedTrace Logo

Use of EL-FIT App to Promote Physical Activity

NCT04604860 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2022-06-07

No results posted yet for this study

Summary

Transplant-eligible patients with cirrhosis and ESLD, age 40-70, MELD \>/= 10 referred to transplant physical therapy will be invited to participate. The investigators will exclude those who lack a smartphone or the understanding of its functionality, lack home wireless internet, or have recurrent/persistent overt hepatic encephalopathy. Following signing of informed consent, each participant will be given a Fitbit Charge 3 and have EL-FIT and Fitbit apps downloaded to their smartphone. After a brief session with a member of the research team explaining the basic components and functionality of EL-FIT and Fitbit, patients will be provided with general physical activity recommendations (as per our current standard of care) and asked to explore all features of EL-FIT and Fitbit apps, up until their 12-week follow-up visit. Phone calls to incentivize physical activity and exercise will be performed by members of the research team.

Conditions

  • End Stage Liver DIsease
  • Cirrhosis, Liver

Interventions

BEHAVIORAL

Fitness intervention

Patients will follow exercise plans designed to promote physical activity (exercise and behavioral coaching).

Sponsors & Collaborators

  • American Association for the Study of Liver Diseases (AASLD)

    collaborator UNKNOWN

  • Pittsburgh Liver Research Center

    collaborator UNKNOWN

  • University of Pittsburgh

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-23
Primary Completion
2022-02-24
Completion
2022-02-24

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04604860 on ClinicalTrials.gov